NHF’s Third Collaborative Learning Exchange will be on -
Managing Complex Cases with Novel Non-Factor Therapies
This live virtual workshop will provide prescribers with an opportunity for interactive discussion on the clinical use of a non-factor therapy (emicizumab) in a particularly difficult case of bleeding in hemophilia A. Participants will be asked to apply their own decision-making skills in considering a complex case study. Our activity will address management challenges and the benefits to collaborating as a team to resolve complications in hemophilia patients receiving novel non-factor therapies.
This activity will be held live on Thursday, June 9, 2022, from 4:00-5:00 pm EDT
2:00-3:00 pm CDT/ 1:00-2:00 pm MDT/ 12:00 -1:00 pm PDT
Target Audience:
These activities are intended for hematologists, physician assistants, and nurse practitioners who regularly prescribe therapies for individuals living with hemophilia A and B.
The event will be moderated by:
Marci Hardy, PhD
Manager of Medical Education Grants
National Hemophilia Foundation
The event presenter is:
Steven W. Pipe, MD
Professor of Pediatrics and Pathology,
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases, Pediatric Medical Director Hemophilia and Coagulation Disorders Program and Director of the Special Coagulation Laboratory at the University of Michigan
The event format will include:
- Latest information on the clinical use of emicizumab and additional challenges demonstrated in the management of patients living with hemophilia A, with and without inhibitors.
- Breakout rooms to discuss and review a complex case study
- Group returning together to summarize findings
- Discussion of lessons learned
Learning Objectives:
- Review the current treatment for and management of acute bleeding in patients with hemophilia A
- Recognize the clinical concerns raised by a challenging patient case with use of a novel non-factor therapy
- Review the clinical indications and recommendations for use of a novel non-factor therapy (emicizumab) in patients with hemophilia A
- Collaborate within the healthcare team shared patient-centered and population focused problem-solving for those experiencing bleeding disorders discussion-based treatment strategies and evidence-based practice
Following the event, a resource document will be shared to support the learning provided by the activity along with a list of supplemental resources.
ACCREDITED CONTINUING EDUCATION
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and National Hemophilia Foundation. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS
The University of Nebraska Medical Center designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.
PHYSICIAN ASSISTANTS
University of Nebraska Medical Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
These trainings are supported by a Cooperative Agreement [Number NU01DD000006], funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.